J & J discontinues sale of talc-based baby powder in U.S., Canada

The company has faced thousands of lawsuits alleging the powder contains asbestos, which the company denies.
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news

Related Links:

ConclusionPeople with cancer residing outside major cities had lower survival from some cancers, which is partly due to the greater socio-economic disadvantage of rural residents.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
In conclusion, we suggest that in the presence of intolerance or resistance to colchicine, interleukin (IL)-1 inhibition could suppress peritoneal inflammation and prevent MSTs. PMID: 32477360 [PubMed - in process]
Source: Pain Physician - Category: Anesthesiology Authors: Tags: Front Immunol Source Type: research
Malignant pleural mesothelioma (MPM) is a treatment recalcitrant tumor with a poor overall survival (OS). Current approved treatment consists of first line chemotherapy that only modestly increases OS, illustrating the desperate need for other treatment options in MPM. Unfortunately, clinical studies that investigate the effectivity of checkpoint inhibitor (CI) treatment failed to improve clinical outcome over current applied therapies. In general, MPM is characterized as an immunological cold tumor with low T-cell infiltration, which could explain the disappointing results of clinical trials investigating CI treatment in ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Doctors, scientists and occupational health experts from across the country are openly criticizing the U.S. Environmental Protection Agency’s recent asbestos draft risk evaluation. At a virtual press conference arranged by the Asbestos Disease Awareness Organization last week, speakers labeled the asbestos evaluation inadequate and in need of serious revision. The year-long evaluation was required as part of the Frank R. Lautenberg Chemical Safety for the 21st Century Act, which was passed in 2016. It amended the original Toxic Substances Control Act, the country’s primary chemicals management law. “I am...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Publication date: Available online 31 May 2020Source: Regulatory Toxicology and PharmacologyAuthor(s): Gary M. Marsh, A. Michael Ierardi
Source: Regulatory Toxicology and Pharmacology - Category: Toxicology Source Type: research
We examined 329 patients from February 2002 to July 2013. There were 131 MPM cases with ADA levels of 32.29 IU/L; 117 LC cases with ADA levels of 21.12 IU/L; 54 benign disease cases with ADA levels of 20.98 IU/L. A significant difference existed in pleural effusion ADA levels between MPM and benign disease patients. Pleural effusion ADA levels were significantly higher in MPM patients. PMID: 32468861 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
Malignant pleural mesothelioma (MPM) is a highly aggressive cancer of the visceral or parietal pleura, with greater than 90% of cases occurring in the setting of asbestos exposure. It is a relatively rare cancer, with an incidence of approximately 10 per 1 million person-years in the United States. It has a long latency period, up to 20 years after asbestos exposure, and the median age of diagnosis is 75 years old. [1,2]
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Rationale: Malignant peritoneal mesothelioma is a rare tumor with a poor prognosis and has no recommended therapy after first-line pemetrexed and platinum-based chemotherapy. Moreover, effects of immune checkpoint inhibitors on peritoneal mesothelioma remains to be elucidated. We herein report the case of a 75-year-old man with peritoneal mesothelioma treated with cisplatin plus pemetrexed and subsequent nivolumab. Patient concerns: A 75-year-old man was referred to our hospital due to lower abdominal pain. Diagnosis: Positron emission tomography-computed tomography (CT) showed the accumulation of fluorodeoxyglucos...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Authors: Bille A, Okiror L, Harling L, Pernazza F, Muzio A, Roveta A, Grosso F Abstract AIM: To report the outcomes and prognosis of patients with malignant pleural mesothelioma (MPM) who present with or develop metastases during treatment. METHODS: This is a retrospective observational study of patients diagnosed with MPM over 7 years. Metastases at presentation or during follow-up were recorded. Multivariate Cox regression was used to evaluate the relationship of clinicopathologic variables and overall survival (OS). Logistic regression was used for propensity score matching of patients to assess chemotherapy...
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
An international, much-anticipated phase III clinical trial that could change standard-of-care treatment for patients with malignant pleural mesothelioma will open soon, pending COVID-19 pandemic restrictions. The randomized trial will be studying the effectiveness of the immunotherapy drug durvalumab (Imfinzi) when used in combination with chemotherapy drugs pemetrexed (Alimta) and cisplatin for mesothelioma. Opening dates may vary by center because of the COVID-19 pandemic that has slowed or stalled clinical trials everywhere. Durvalumab produces an antibody that helps a patient’s own immune system kill tumor cell...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Babies | Canada Health | Health | Lawsuits | Legislation